당단백질 시장 규모, 점유율 및 동향 분석 보고서 : 제품 유형별, 당쇄수식 유형별, 기술별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Glycoprotein Market Summary

The global glycoprotein market size was valued at USD 1.1 billion in 2025 and is projected to grow from USD 1.3 billion in 2026 to USD 2.8 billion by 2033, at a CAGR of 12.1% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 37.0% in 2025. The market growth is driven by the increasing demand for glycoproteins in biopharmaceuticals, diagnostics, vaccine development, and life science research.

Global Glycoprotein Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global glycoprotein market report on the basis of product type, glycosylation type, technique, end-use, and region

• Product Type Outlook (Revenue, USD Million, 2021 - 2033)
• Reagents
• Assay Kits
• Purification Products
• Enzymes
• Standards & Controls
• Others
• Glycosylation Type Outlook (Revenue, USD Million, 2021 - 2033)
• N-Linked Glycoproteins
• O-Linked Glycoproteins
• Other Glycosylation Types
• Technique Outlook (Revenue, USD Million, 2021 - 2033)
• Mass Spectrometry
• Chromatography
• Electrophoresis
• Lectin-Based Analysis
• Immunoassays
• Capillary Electrophoresis
• Glycan Labeling & Detection
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations (CROs)
• Clinical & Diagnostic Laboratories
• Government & Regulatory Laboratories
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Products Type Segment
    • 1.1.1.2. Glycosylation Type Segment
    • 1.1.1.3. Technique Segment
    • 1.1.1.4. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis:
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
  • 1.9.2. List of Secondary Sources
  • 1.9.3. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing demand for glycoprotein-based biologics and biosimilars
    • 3.2.1.2. Rising prevalence of cancer, autoimmune, and infectious diseases
    • 3.2.1.3. Growing investments in glycomics and proteomics research
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Complexity of glycosylation and quality control
    • 3.2.2.2. High production and purification costs
  • 3.2.3. Market Opportunities Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Economic landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Product Type Business Analysis

• 4.1. Segment Dashboard
• 4.2. Glycoprotein Market: Product Type Movement Analysis
• 4.3. Reagents
  • 4.3.1. Reagents Market, 2021-2033 (USD Million)
• 4.4. Assay Kits
  • 4.4.1. Assay Kits Market, 2021-2033 (USD Million)
• 4.5. Purification Products
  • 4.5.1. Purification Products Market, 2021-2033 (USD Million)
• 4.6. Enzymes
  • 4.6.1. Enzymes Market, 2021-2033 (USD Million)
• 4.7. Standards & Controls
  • 4.7.1. Standards & Controls Market, 2021-2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market, 2021-2033 (USD Million)

Chapter 5. Glycosylation Type Business Analysis

• 5.1. Segment Dashboard
• 5.2. Glycoprotein Market: Glycosylation Type Movement Analysis
• 5.3. N-Linked Glycoproteins
  • 5.3.1. N-Linked Glycoproteins Market, 2021-2033 (USD Million)
• 5.4. O-Linked Glycoproteins
  • 5.4.1. O-Linked Glycoproteins Market, 2021-2033 (USD Million)
• 5.5. Other Glycosylation Types
  • 5.5.1. Other Glycosylation Types Market, 2021-2033 (USD Million)

Chapter 6. Technique Business Analysis

• 6.1. Segment Dashboard
• 6.2. Glycoprotein Market: Technique Movement Analysis
• 6.3. Mass Spectrometry
  • 6.3.1. Mass Spectrometry Market, 2021-2033 (USD Million)
• 6.4. Chromatography
  • 6.4.1. Chromatography Market, 2021-2033 (USD Million)
• 6.5. Electrophoresis
  • 6.5.1. Electrophoresis Market, 2021-2033 (USD Million)
• 6.6. Lectin-Based Analysis
  • 6.6.1. Lectin-Based Analysis Market, 2021-2033 (USD Million)
• 6.7. Immunoassays
  • 6.7.1. Immunoassays Market, 2021-2033 (USD Million)
• 6.8. Capillary Electrophoresis
  • 6.8.1. Capillary Electrophoresis Market, 2021-2033 (USD Million)
• 6.9. Glycan Labeling & Detection
  • 6.9.1. Glycan Labeling & Detection Market, 2021-2033 (USD Million)
• 6.10. Others
  • 6.10.1. Others Market, 2021-2033 (USD Million)

Chapter 7. End Use Business Analysis

• 7.1. Segment Dashboard
• 7.2. Glycoprotein Market: End Use Movement Analysis
• 7.3. Pharmaceutical & Biotechnology Companies
  • 7.3.1. Pharmaceutical & Biotechnology Companies Market, 2021-2033 (USD Million)
• 7.4. Academic & Research Institutes
  • 7.4.1. Academic & Research Institutes Market, 2021-2033 (USD Million)
• 7.5. Contract Research Organizations (CROs)
  • 7.5.1. Contract Research Organizations (CROs) Market, 2021-2033 (USD Million)
• 7.6. Clinical & Diagnostic Laboratories
  • 7.6.1. Clinical & Diagnostic Laboratories Market, 2021-2033 (USD Million)
• 7.7. Government & Regulatory Laboratories
  • 7.7.1. Government & Regulatory Laboratories Market, 2021-2033 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Glycoprotein Market Share By Region, 2025 & 2033
• 8.2. North America
  • 8.2.1. North America Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. U.S. Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Canada Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Competitive Scenario
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Mexico Glycoprotein Market, 2021 - 2033 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. UK Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Germany Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. France Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Italy Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Spain Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Denmark Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Sweden Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Norway Glycoprotein Market, 2021 - 2033 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Japan Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. China Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. India Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.4.5. Australia
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Australia Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.4.6. Thailand
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Thailand Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.4.7. South Korea
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. South Korea Glycoprotein Market, 2021 - 2033 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Brazil Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Argentina Glycoprotein Market, 2021 - 2033 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. South Africa Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Saudi Arabia Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. UAE Glycoprotein Market, 2021 - 2033 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Kuwait Glycoprotein Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Company Market Share/ Position Analysis, 2025
• 9.3. Strategy Mapping
• 9.4. Company Profiles/Listing
  • 9.4.1. Thermo Fisher Scientific Inc.
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Merck KGaA
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Agilent Technologies, Inc.
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Waters Corporation
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Bruker
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Danaher Corporation
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Biotium
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Bio-Techne
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. GenScript
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Shimadzu Corporation
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives
  • 9.4.11. Sartorius AG
    • 9.4.11.1. Overview
    • 9.4.11.2. Financial Performance
    • 9.4.11.3. Product Benchmarking
    • 9.4.11.4. Strategic Initiatives
  • 9.4.12. Bio-Rad Laboratories, Inc.
    • 9.4.12.1. Overview
    • 9.4.12.2. Financial Performance
    • 9.4.12.3. Product Benchmarking
    • 9.4.12.4. Strategic Initiatives
  • 9.4.13. Sino Biological, Inc.
    • 9.4.13.1. Overview
    • 9.4.13.2. Financial Performance
    • 9.4.13.3. Product Benchmarking
    • 9.4.13.4. Strategic Initiatives